KDR and neoplasm: Despite increased MET and RET expression in SCNPC, our results cumulatively suggest that cabozantinib acted through mouse endothelial VEGFR2 and inhibited angiogenesis leading to hypoxia and tumor cell death regardless of MET/RET status in both LuCaP SCNPC PDX models.